Primary GBM, accounting for over 90% of human GBMs, develops rapidly or de novo with no prior clinical disease. Large-scale genomic analyses have contributed greatly to the definition of the overall glioma landscape and datasets (TCGA) have enabled the division of GBMs into subclasses based on their genomic, transcriptomic, and signal transduction patterns. Sadly, despite these insights into the genetics of the disease and advances in neurosurgery, radiation and chemotherapy, its dismal prognosis has not changed significantly. The current paradigm for glioblastoma (GBM) therapy is based on the concept that each patient is treated with a protocol that is most likely to prolong life (temozolamide and radiation) in a majority of patients. The treatment may not be efficacious for any given individual even though it may work with most patients with a similar pathology. If the treatment fails, second-line treatments, usually experimental are administered, although by this time it may be too late for many patients with glioblastoma. This concept is obviously unacceptable in the current era wherein the technology for whole genome sequencing is a reality and thus enabling personalized medicine using targeted agents based on genetic alterations of each patient is possible. Project 1 will investigate in mouse model using human GBM explants, if stratification of patients based on the four molecular classes of GBM followed by optimization of single and combination therapies for each of these subclasses can enhance outcomes. Project 2 using a mouse model of adult onset GBM, investigate the sequential accumulation of genetic lesions that initiate gliomagenesis and also identify genetic/proteomic alterations that transform a slow growing lesion into aggressive disease, as well as alterations that result in therapeutic resistance. This information will be used to test the hypothesis that targeted inhibition of initiating oncogenic pathways early in gliomagenesis will enhance survival. Project 3 will undertake prospective and retrospective GBM clinical trials to evaluate quantitative MR biomarker metrics for early prediction of treatment efficacy and GBM recurrence. The overall integration of the program components will provide novel insights into the oncogenic evolution of the disease (Project 2) and the application of targeted agents directed against these oncogenic events in an individualized manner (Project 1) with the use of novel imaging technologies as predictive surrogates (Project 3) will significantly impact this patient population. All three research projects will be supported by four cores, the administrative core (Core A), an imaging core (Core B), a bioinformatics core (Core C) and the biostatistics core (Core D).

Public Health Relevance

Overall, this research effort will provide the rationale for initiation of clinical trias with combinations of molecularly targeted therapies for the treatment of brain tumors. In addition, imaging biomarkers for early assessment of treatment response and recurrence will be identified and validated. The overall project will provide the foundation for clinical delivery of individualized patient care leading to improved outcome.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA085878-10A1
Application #
8476336
Study Section
Special Emphasis Panel (ZCA1-RPRB-W (J1))
Program Officer
Menkens, Anne E
Project Start
2000-04-01
Project End
2018-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
10
Fiscal Year
2013
Total Cost
$2,012,389
Indirect Cost
$653,604
Name
University of Michigan Ann Arbor
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Galbán, Stefanie; Apfelbaum, April A; Espinoza, Carlos et al. (2017) A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis. Mol Cancer Ther 16:2340-2350
Hu, Xin; Martinez-Ledesma, Emmanuel; Zheng, Siyuan et al. (2017) Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol 19:786-795
Nyati, Shyam; Young, Grant; Ross, Brian Dale et al. (2017) Quantitative and Dynamic Imaging of ATM Kinase Activity. Methods Mol Biol 1596:131-145
Chen, Daiqin; Yang, Dongzhi; Dougherty, Casey A et al. (2017) In Vivo Targeting and Positron Emission Tomography Imaging of Tumor with Intrinsically Radioactive Metal-Organic Frameworks Nanomaterials. ACS Nano 11:4315-4327
Galbán, C J; Hoff, B A; Chenevert, T L et al. (2017) Diffusion MRI in early cancer therapeutic response assessment. NMR Biomed 30:
Martinez, Carlos H; Diaz, Alejandro A; Meldrum, Catherine et al. (2017) Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS. Am J Respir Crit Care Med 195:464-472
Galbán, Stefanie; Al-Holou, Wajd N; Wang, Hanxiao et al. (2017) MRI-Guided Stereotactic Biopsy of Murine GBM for Spatiotemporal Molecular Genomic Assessment. Tomography 3:9-15
Yang, Dongzhi; Comeau, Anthony; Bowen, Wayne D et al. (2017) Design and Investigation of a [18F]-Labeled Benzamide Derivative as a High Affinity Dual Sigma Receptor Subtype Radioligand for Prostate Tumor Imaging. Mol Pharm 14:770-780
Belloli, Elizabeth A; Degtiar, Irina; Wang, Xin et al. (2017) Parametric Response Mapping as an Imaging Biomarker in Lung Transplant Recipients. Am J Respir Crit Care Med 195:942-952
Pompe, Esther; Galbán, Craig J; Ross, Brian D et al. (2017) Parametric response mapping on chest computed tomography associates with clinical and functional parameters in chronic obstructive pulmonary disease. Respir Med 123:48-55

Showing the most recent 10 out of 163 publications